Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial

OBJECTIVE: This study evaluated the safety and preliminary efficacy of vorolanib, a novel tyrosine kinase inhibitor, for treatment of patients with advanced solid tumors. METHODS: During dose escalation, patients received increasing doses of oral vorolanib (50−250 mg once daily) in cycles of four we...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Chin J Cancer Res
Main Authors: Song, Yan, Wang, Jinwan, Ren, Xiubao, Jin, Jie, Mao, Li, Liang, Chris, Ding, Lieming, Yang, Lin
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2021
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7941683/
https://ncbi.nlm.nih.gov/pubmed/33707933
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21147/j.issn.1000-9604.2021.01.11
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados